Advertisement

HindustanTimes Sat,20 Sep 2014

Ranbaxy gets Indian drug regulator's nod to sell malaria drug

PTI  New Delhi, October 21, 2013
First Published: 15:38 IST(21/10/2013) | Last Updated: 17:58 IST(21/10/2013)

Drug major Ranbaxy Laboratories today said it has received Indian drug regulator's approval to market SynriamTM for treating malaria caused by Plasmodium vivax parasite.

Advertisement

The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market SynriamTM in India for the treatment of uncomplicated malaria in adults caused by Plasmodium vivax parasite, Ranbaxy Laboratories Ltd said in a statement.

Last year, the Gurgaon-based firm had launched SynriamTM for treatment of uncomplicated Plasmodium falciparum malaria in India.

"Phase III clinical trials for the drug, conducted in India successfully demonstrated the efficacy and tolerability of Synriam as comparable to chloroquine," the company added.

The company has also received permission to conduct phase III clinical trials for the paediatric formulation in paediatric patients of uncomplicated Plasmodium falciparum malaria, it said.

"This approval makes SynriamTM one of the few therapies in the world that successfully treats both, Plasmodium vivax and Plasmodium falciparum malaria," Ranbaxy CEO and Managing Director Arun Sawhney said.

Ranbaxy is working to make this new treatment available in African, Asian and South American markets where malaria is rampant, he added.

"The company has filed New Drug Applications (NDAs) for marketing SynriamTM in some African countries and will be filing more applications during the year. Once approved, the product will be launched in these markets," Sawhney said.

According to the World Malaria Report 2012 published by WHO, India witnesses about 13 lakh confirmed cases of malaria each year, about 50 % of which are caused by Plasmodium vivax, the second most important species after Plasmodium falciparum.

Shares of Ranbaxy were trading at Rs. 402.40 on the BSE in afternoon trade, up 2.93 % from its previous close.


Advertisement
more from Business

Larry Ellison steps down as Oracle CEO after 37 years

Larry Ellison, co-founder and leader of Oracle Corp for 37 years, stepped aside as chief executive officer on Thursday, to be replaced by co-CEOs Safra Catz and Mark Hurd, raising questions about a job-sharing arrangement that has had a fraught record elsewhere.
markets
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved